Shenzhen Neptunus Interlong Bio-technique Company Limited (NEP Interlong, 08329) released a supplemental profit warning stating that profit attributable to shareholders for FY2025 is projected to fall by about 240%–280% versus FY2024.
The projected downturn is primarily linked to an impairment provision on goodwill arising from the earlier acquisition of Beijing Neptunus Zhongxin Pharmaceutical Co., Limited.
Management is finalising FY2025 results, with the audited figures scheduled for release on 25 March 2026.
Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments